molsidomine has been researched along with Hypertension, Pulmonary in 17 studies
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study addressed whether combined treatment with a phosphodiesterase type 5 inhibitor, sildenafil, and a nitric oxide donor, molsidomine, prevents development of pulmonary hypertension in chronic hypoxic rats." | 7.73 | Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. ( Andersen, CU; Mulvany, MJ; Simonsen, U, 2005) |
| "We present three patients with pulmonary hypertension in Takayasu's arteritis who showed long-term favorable response, clinically and hemodynamically, to nitric oxide donor molsidomine." | 7.71 | Nitric oxide and molsidomine in the management of pulmonary hypertension in Takayasu's arteritis. ( Kim, DS; Kim, WD; Kim, WS; Koh, Y; Lee, SD; Lim, CM; Shim, TS, 2001) |
| "Monocrotaline (MCT)-induced pulmonary hypertension (PH) is associated with impaired endothelium-dependent nitric oxide (NO)-mediated relaxation." | 7.69 | Role of inhibition of nitric oxide production in monocrotaline-induced pulmonary hypertension. ( Gewitz, MH; Gloster, ES; Mathew, R; Sundararajan, T; Thompson, CI; Zeballos, GA, 1997) |
| "The present study addressed whether combined treatment with a phosphodiesterase type 5 inhibitor, sildenafil, and a nitric oxide donor, molsidomine, prevents development of pulmonary hypertension in chronic hypoxic rats." | 3.73 | Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. ( Andersen, CU; Mulvany, MJ; Simonsen, U, 2005) |
| "We present three patients with pulmonary hypertension in Takayasu's arteritis who showed long-term favorable response, clinically and hemodynamically, to nitric oxide donor molsidomine." | 3.71 | Nitric oxide and molsidomine in the management of pulmonary hypertension in Takayasu's arteritis. ( Kim, DS; Kim, WD; Kim, WS; Koh, Y; Lee, SD; Lim, CM; Shim, TS, 2001) |
| "To this end, we determined pulmonary prostacyclin synthase (PGIS) gene expression, circulating levels of the stable prostacyclin metabolite 6-keto prostaglandin F(1alpha) (6-keto-PGF(1alpha)), pulmonary endothelin (ET)-1 gene expression, and ET-1 plasma levels in rats exposed to 4 weeks of hypoxia (10% O(2)) in the presence or absence of either the nitric oxide (NO) donor molsidomine (MD, 15 mg/kg/day) or the ET-A receptor antagonist LU135252 (LU, 50 mg/kg/day)." | 3.71 | Increased pulmonary prostacyclin synthesis in rats with chronic hypoxic pulmonary hypertension. ( Blumberg, FC; Lorenz, C; Pfeifer, M; Riegger, GA; Sandner, P; Wolf, K, 2002) |
| "Monocrotaline (MCT)-induced pulmonary hypertension (PH) is associated with impaired endothelium-dependent nitric oxide (NO)-mediated relaxation." | 3.69 | Role of inhibition of nitric oxide production in monocrotaline-induced pulmonary hypertension. ( Gewitz, MH; Gloster, ES; Mathew, R; Sundararajan, T; Thompson, CI; Zeballos, GA, 1997) |
| "In the treatment of pulmonary hypertension, this pathway is exogenously activated using inhaled NO or other pharmacological agents." | 1.37 | Attenuated vasodilatation in lambs with endogenous and exogenous activation of cGMP signaling: role of protein kinase G nitration. ( Aggarwal, S; Black, SM; Datar, S; Fineman, JR; Fratz, S; Gross, CM; Kalkan, G; Kumar, S; Oishi, P; Schreiber, C, 2011) |
| "Molsidomine (M) is a recent nitrates-like drug acting for a longer time than the classical nitrates." | 1.28 | Acute effect of molsidomine on pulmonary circulation of patients with chronic obstructive pulmonary disease. ( Frans, A; Lampert, E; Mwepu, AK, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (23.53) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, S | 1 |
| Gross, CM | 1 |
| Kumar, S | 1 |
| Datar, S | 1 |
| Oishi, P | 1 |
| Kalkan, G | 1 |
| Schreiber, C | 1 |
| Fratz, S | 1 |
| Fineman, JR | 1 |
| Black, SM | 1 |
| Andersen, CU | 1 |
| Mulvany, MJ | 1 |
| Simonsen, U | 1 |
| Schwenke, DO | 1 |
| Pearson, JT | 1 |
| Tsuchimochi, H | 1 |
| Mori, H | 1 |
| Shirai, M | 1 |
| Senenko, AN | 1 |
| Ipatov, PV | 1 |
| Krynskiĭ, OM | 1 |
| Kuznetsov, EI | 1 |
| Jahed, MM | 1 |
| Girard, C | 1 |
| Neidecker, J | 1 |
| Laroux, MC | 1 |
| Champsaur, G | 1 |
| Estanove, S | 1 |
| Mathew, R | 1 |
| Gloster, ES | 1 |
| Sundararajan, T | 1 |
| Thompson, CI | 1 |
| Zeballos, GA | 1 |
| Gewitz, MH | 1 |
| Berkenbosch, JW | 2 |
| Baribeau, J | 2 |
| Perreault, T | 2 |
| Wanstall, JC | 1 |
| Gambino, A | 1 |
| Thomas, BJ | 1 |
| Lee, SD | 1 |
| Kim, DS | 1 |
| Shim, TS | 1 |
| Lim, CM | 1 |
| Koh, Y | 1 |
| Kim, WS | 1 |
| Kim, WD | 1 |
| Blumberg, FC | 2 |
| Wolf, K | 2 |
| Sandner, P | 2 |
| Lorenz, C | 2 |
| Riegger, GA | 2 |
| Pfeifer, M | 2 |
| Barrington, KJ | 1 |
| Decker, ER | 1 |
| Wu, C | 1 |
| Brock, TA | 1 |
| Lampert, E | 2 |
| Tuo, N | 1 |
| Frans, A | 2 |
| Lonsdorfer, J | 1 |
| Mwepu, AK | 1 |
| Renard, M | 1 |
| Verhoeven, A | 1 |
| Liebens, I | 1 |
| Bernard, R | 1 |
| Daskalov, TR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1 Study of the Safety and Pharmacokinetics of Perioperative IV L-carnitine Administration in Patients With Congenital Heart Disease With Increased Pulmonary Blood Flow[NCT01825369] | Phase 1 | 0 participants (Actual) | Interventional | 2014-12-31 | Withdrawn (stopped due to Changes to cardiac surgery program) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for molsidomine and Hypertension, Pulmonary
| Article | Year |
|---|---|
Disappearance of molsidomine effects on pulmonary circulation of patients with chronic obstructive pulmonary disease after a three week treatment.
Topics: Blood Gas Analysis; Double-Blind Method; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Disease | 1991 |
16 other studies available for molsidomine and Hypertension, Pulmonary
| Article | Year |
|---|---|
Attenuated vasodilatation in lambs with endogenous and exogenous activation of cGMP signaling: role of protein kinase G nitration.
Topics: Administration, Inhalation; Animals; Animals, Newborn; Cells, Cultured; Cyclic GMP; Cyclic GMP-Depen | 2011 |
Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats.
Topics: Acetylcholine; Actins; Animals; Atrial Natriuretic Factor; Body Weight; Dose-Response Relationship, | 2005 |
Exogenous nitric oxide centrally enhances pulmonary reactivity in the normal and hypertensive rat.
Topics: Animals; Blood Pressure; Cardiac Output; Central Nervous System; Heart Rate; Hypertension, Pulmonary | 2005 |
[Changes in blood pressure in the pulmonary artery in myocardial infarct].
Topics: Adult; Aged; Blood Pressure; Female; Heart Rate; Humans; Hypertension, Pulmonary; Male; Middle Aged; | 1984 |
[Acute hemodynamic effects of intravenous administration of molsidomine in secondary pulmonary hypertension and right heart failure].
Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Failure; Hemodyn | 1994 |
Inhaled nitric oxide in pulmonary hypertension after total repair of total anomalous pulmonary venous return.
Topics: Administration, Inhalation; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Infant; Male; | 1993 |
Role of inhibition of nitric oxide production in monocrotaline-induced pulmonary hypertension.
Topics: Animals; Arterioles; Blood Pressure; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Inject | 1997 |
Decreased synthesis and vasodilation to nitric oxide in piglets with hypoxia-induced pulmonary hypertension.
Topics: Animals; Animals, Newborn; Arginine; Blood Vessels; Cyclic GMP; Hypertension, Pulmonary; Hypoxia; In | 2000 |
KRN2391: dual action on rat pulmonary artery and no loss of potency in pulmonary hypertension.
Topics: Adenosine Triphosphate; Animals; Cromakalim; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gl | 2000 |
Nitric oxide and molsidomine in the management of pulmonary hypertension in Takayasu's arteritis.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Molsid | 2001 |
The NO donor molsidomine reduces endothelin-1 gene expression in chronic hypoxic rat lungs.
Topics: Animals; Chronic Disease; Disease Models, Animal; Endothelin-1; Enzyme Inhibitors; Gene Expression R | 2001 |
TBC3711, an ET(A) receptor antagonist, reduces neonatal hypoxia-induced pulmonary hypertension in piglets.
Topics: Animals; Animals, Newborn; Cell Line; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hyperte | 2001 |
Increased pulmonary prostacyclin synthesis in rats with chronic hypoxic pulmonary hypertension.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Chronic Disease; Cytochrome P-450 Enzyme System; Endothelin R | 2002 |
Acute effect of molsidomine on pulmonary circulation of patients with chronic obstructive pulmonary disease.
Topics: Heart Failure; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male; Middle Aged; Molsi | 1989 |
Blood gas and hemodynamic changes induced by the treatment of pulmonary congestion with vasodilators in the acute phase of myocardial infarction.
Topics: Adult; Aged; Carbon Dioxide; Female; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; I | 1986 |
Application of a combination of sublingually administered vasodilating drugs for rapid action on pulmonary hypertension in patients with cardiac asthma and with pulmonary oedema.
Topics: Administration, Oral; Adult; Aged; Drug Therapy, Combination; Dyspnea, Paroxysmal; Female; Heart Fai | 1987 |